Section Arrow
Quote
INTS.NASDAQ
- Intensity Therapeutics Inc.
Quotes are at least 15-min delayed:2026/05/10 15:12 EDT
Regular Hours
Last
 5.09
-0.02 (-0.39%)
Day High 
5.2099 
Prev. Close
5.11 
1-M High
5.75 
Volume 
20.68K 
Bid
5.01
Ask
5.35
Day Low
5.04 
Open
5.17 
1-M Low
4.98 
Market Cap 
13.54M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 5.19 
20-SMA 5.26 
50-SMA 6.07 
52-W High 43.5 
52-W Low 4.6325 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-8.56/-2.95
Enterprise Value
13.62M
Balance Sheet
Book Value Per Share
4.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TRAWTraws Pharma Inc2.18+0.48+28.24%2.07PE
VRAXVirax Biolabs Group Limited0.171+0.036+26.67%-- 
ASBPAspire Biopharma Holdings Inc.0.185+0.03+19.35%-- 
INOInovio Pharmaceuticals1.46+0.09+6.57%-- 
MRNAModerna54.35+5.81+11.97%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves thedirect injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.